EHA 2024 | Novel therapeutic strategies in ALL
Jae Park, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses novel therapeutic strategies for managing acute lymphoblastic leukemia (ALL). He highlights advancements in immunotherapy, including CAR T-cells, which have proven effective in relapsed/refractory (R/R) cases and are now being explored for earlier treatment stages and T-cell ALL. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So for B-cell ALL, we have seen dramatic improvement a lot for the immunotherapy. I think for, for example, Ph+ ALL that we have seen that these patients may not even need intensive chemotherapy to be cured as well too. So I think it will be interesting to look at the CAR T-cell therapy, now we have shown the efficacy and better toxicity profiles in the relapsed/refractory setting. These agents are now moving into the frontline setting in MRD positive settings and hopefully also in consolidation to try to shorten the whole duration of ALL therapy...
So for B-cell ALL, we have seen dramatic improvement a lot for the immunotherapy. I think for, for example, Ph+ ALL that we have seen that these patients may not even need intensive chemotherapy to be cured as well too. So I think it will be interesting to look at the CAR T-cell therapy, now we have shown the efficacy and better toxicity profiles in the relapsed/refractory setting. These agents are now moving into the frontline setting in MRD positive settings and hopefully also in consolidation to try to shorten the whole duration of ALL therapy. So it’s not a novel agent, but another way, a novel way of using that therapy, which is kind of quite interesting. We’re now beginning to see more CAR T-cell therapy targeting T-cells. T-ALL, so CD-7 targeted CAR-T cells, we have seen several data now that’s been presented in a multicenter study that’s going on, so that will be kind of an interesting study as well for ALL patients.
Read more...
Disclosures
Research Funding: Autolus Therapeutic, Genentech, Inc., Fate Therapeutics, Servier, Incyte, Takeda, Sobi; Consultancy: Curocell, Affyimmune, Amgen, Artiva Biotherapeutics, Bright Pharmacetuicals, Be Biopharma, BeiGene, Servier, Allogene, Intella, Takeda, Sobi, Pfizer, Kite, Minerva Bio, Synthekine; Current holder of stock options in a privately-held company: Artiva Biotherapeutics; Membership on Board of Directors or advisory committee: Artiva Biotherapeutics, Allogene, GC Cell.
